Enterokinase,Recombinant,Expressed in E.coli大腸桿菌表達(dá)重組腸激酶(不帶標(biāo)簽)注意事項(xiàng)1.本產(chǎn)品所講述的緩沖體系需要自行配置。2.不建議37℃條件下酶切，可能會(huì)有非特異性酶切出現(xiàn)。3.在＞200mM咪唑，或＞200mMNaCl，或＞5%甘油，酶切會(huì)受到影響。如果樣品溶液中含有上述成分的一種或多種，為獲得理想的酶切結(jié)果，請(qǐng)先將樣品透析到25mMTris-HCl8.0緩沖液中，然后再進(jìn)行酶切實(shí)驗(yàn)；若不方便透析，可將樣品稀釋到咪唑含量在100mM以下，NaCl濃度在50mM以下，甘油濃度小于5%以下進(jìn)行酶切，酶的用量與蛋白比例不變；若干擾因素很多，且不便去除，需要適當(dāng)增加酶量或延長(zhǎng)酶切時(shí)間，有助于得到理想的酶切效果。4.磷酸鹽對(duì)Enterokinase有很強(qiáng)的抑制作用，痕量的磷酸鹽都會(huì)嚴(yán)重影響Enterokinase的活性，因此在酶切體系內(nèi)不能存在磷酸鹽。5.本品是具有高酶活力重組腸激酶，切割蛋白使用量少，可不考慮除去。后續(xù)如需去除重組腸激酶，可用陰離子交換樹(shù)脂（如DEAE-FF）對(duì)其進(jìn)行洗脫。推薦洗脫條件如下：平衡緩沖液：25mMTris-HClpH8.0洗脫緩沖液：25mMTris-HClpH8.0，含100mMNaCl6.蛋白酶切效果不好，可適當(dāng)增加酶量，或適當(dāng)延長(zhǎng)酶切時(shí)間。甲磺酸達(dá)比加群酯是一種抗凝藥，通過(guò)競(jìng)爭(zhēng)結(jié)合凝血酶的纖維蛋白特異結(jié)合位點(diǎn)，從而抑制血栓的形成。Recombinant Human OPG-Fc

Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.Recombinant Mouse CD24 Protein,mFc Tag通過(guò)泛素-蛋白體途徑(UPP)中的酶與底物蛋白共價(jià)連接，并在26S蛋白體降解ATP依賴的細(xì)胞蛋白中發(fā)揮主要作用。

Recombinant Biotinylated Human KIR2DL1 Protein,His-Avi Tag性能參數(shù)分子別名（Synonyms）CD158A;CD158Ankat1;cl-42表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）BiotinylatedHumanKIR2DL1ProteinisexpressedfromHEK293withHistagandAvitagattheC-Terminus.ItcontainsHis22-Arg242.[Accession|P43626]分子量大?。∕olecularWeight）TheproteinhasapredictedMWof27.1kDa.Duetoglycosylation,theproteinmigratesto48-60kDabasedonSDS-PAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedbySDS-PAGEandHPLC.制劑（Formulation）Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法（Reconstitution）Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.儲(chǔ)存條件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.

Coronavirusesarecommonlycomprisedoffourstructuralproteins:Spikeprotein(S),Envelopeprotein(E),Membraneprotein(M)andNucleocapsidprotein(N).TheSARS-CoV-2Sproteinisaglycoproteinthatmediatesmembranefusionandviralentry.TheSproteinishomotrimeric,witheach~180-kDamonomerconsistingoftwosubunits,S1andS2.TheRBDofSARS-CoV-2bindsametallopeptidase,angiotensin-convertingenzyme2(ACE-2).產(chǎn)品性質(zhì)別名SproteinRBD;SglycoproteinRBD;SpikeproteinRBDAccessionQHD43416.1表達(dá)區(qū)間及表達(dá)系統(tǒng)RecombinantSARS-CoV-2SpikeRBD(OmicronBA.4/BA.5/BA.5.1.3/BA.5.2)ProteinisexpressedfromExpi293withHistagattheC-terminal.ItcontainsArg319-Phe541(G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,L452R,S477N,T478K,E484A,F486V,Q498R,N501Y,Y505H).PreScission Protease是一種由人鼻病毒14型的3C蛋白酶（human rhinovirus）和GST組成的融合蛋白。

SARS-CoV-2,whichcausestheglobalpandemiccoronavirusdisease2019(Covid-19),belongstoafamilyofvirusesknownascoronaviruses.TheSARS-CoV-2Sproteinisaglycoproteinthatmediatesmembranefusionandviralentry.TheRBDofSARS-CoV-2bindsametallopeptidase,angiotensin-convertingenzyme2(ACE-2).SeveralemergingSARS-CoV-2genomeshavebeenidentifiedincludingtheOmicron,orB.1.1.529,variant.FirstidentifiedinNovember2021inSouthAfrica,theOmicronvariantquicklybecamethepredominantSARS-CoV-2variantandisconsideredavariantofconcern(VOC).TheOmicronvariantcontains15mutationsinRBDdomainthatpotentiallyaffectviralfitnessandtransmissibility.ThemajorityofthemutationsareinvolvedinACE-2bindingandOmicronbindsACE-2withgreateraffinity,potentiallyexplainingitsincreasedtransmissibility.Severalofthesemutationsarealsoidentifiedinfacilitatingimmuneescapeandreducingneutralizationactivitytoseveralmonoclonalantibodies.FGF-18與FGF R2C，F(xiàn)GF R3C以及高爾基蛋白GLG1結(jié)合，并誘導(dǎo)星形膠質(zhì)細(xì)胞和小膠質(zhì)細(xì)胞。Recombinant Mouse sTNF RI/TNFRSF1A

在體內(nèi)，活化的X因子（Factor Xa）切割凝血酶原，釋放出活性肽并將凝血酶切割成具有催化活性的α-凝血酶。Recombinant Human OPG-Fc

Recombinant Biotinylated Human ENPP-3 Protein,His-Avi Tag性能參數(shù)分子別名（Synonyms）NPP3;E-NPP3;PD-Ibeta表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）BiotinylatedHumanENPP-3ProteinisexpressedfromHEK293withHistagandAvitagattheN-Terminus.ItcontainsLeu48-Ile875.[Accession|O14638]分子量大?。∕olecularWeight）TheproteinhasapredictedMWof99.97kDa.Duetoglycosylation,theproteinmigratesto110-130kDabasedonSDS-PAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedbySDS-PAGEandHPLC.制劑（Formulation）Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法（Reconstitution）Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.儲(chǔ)存條件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.3-6months,-85~-65℃understerileconditionsafterreconstitution.Recombinant Human OPG-Fc

浦斯瑞（上海）生物醫(yī)藥有限公司是一家有著先進(jìn)的發(fā)展理念，先進(jìn)的管理經(jīng)驗(yàn)，在發(fā)展過(guò)程中不斷完善自己，要求自己，不斷創(chuàng)新，時(shí)刻準(zhǔn)備著迎接更多挑戰(zhàn)的活力公司，在江蘇省等地區(qū)的化工中匯聚了大量的人脈以及**，在業(yè)界也收獲了很多良好的評(píng)價(jià)，這些都源自于自身的努力和大家共同進(jìn)步的結(jié)果，這些評(píng)價(jià)對(duì)我們而言是比較好的前進(jìn)動(dòng)力，也促使我們?cè)谝院蟮牡缆飞媳３謯^發(fā)圖強(qiáng)、一往無(wú)前的進(jìn)取創(chuàng)新精神，努力把公司發(fā)展戰(zhàn)略推向一個(gè)新高度，在全體員工共同努力之下，全力拼搏將共同浦斯瑞（上海）生物醫(yī)藥供應(yīng)和您一起攜手走向更好的未來(lái)，創(chuàng)造更有價(jià)值的產(chǎn)品，我們將以更好的狀態(tài)，更認(rèn)真的態(tài)度，更飽滿的精力去創(chuàng)造，去拼搏，去努力，讓我們一起更好更快的成長(zhǎng)！